Oncology · Endometrial CancerTrial Updateclinicalmid-term

Phase II Trial of Olaparib and Durvalumab Combinations in Recurrent Endometrial Cancer

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AstraZeneca66 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 6:31:08 AM

Assessment confidence: 89% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase II trial of olaparib and durvalumab combinations is critical as it may redefine treatment standards for recurrent endometrial cancer. Positive outcomes could significantly impact competitive positioning and market dynamics in oncology. Regulatory context from FDA (FDA AP — IMFINZI (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (24 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial outcomes as successful results may influence treatment guidelines and competitive positioning. The strongest clinical anchor is Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov), entity match (olaparib); patient population match (recurrent). In Oncology · Endometrial Cancer, 5 regulatory and 4 competitive items passed relevance filtering for AstraZeneca.

Competitive Pressure

The most relevant competitive pressure comes from Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated (Humanexa Signals) — entity match (oncology). Secondary pressure from Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer. This trial could position the involved therapies as potential new standards of care in a challenging treatment landscape for endometrial cancer.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — IMFINZI (SUPPL) (FDA). Entity match (astrazeneca); Regulatory pathway relevance (nda). The trial outcomes may influence future regulatory approvals and treatment guidelines, impacting how these therapies are positioned in the market.

Key Risks

Elevated medium regulatory exposure for AstraZeneca could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on AstraZeneca through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

Successful trial results could lead to increased market share for the involved therapies, potentially establishing them as new standards of care, which would drive revenue growth.
Upside for AstraZeneca may improve if Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov) delivers favorable follow-through.
Upside for AstraZeneca may improve if Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea (ClinicalTrials.gov) delivers favorable follow-through.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Oncology · NSCLC · Trial Update · If successful, this combination could enhance treatment options and market share for osimertinib, impacting competitors in the NSCLC space.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and overall survival data from the trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — IMFINZI (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — IMFINZI (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Entity match (oncology)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govhigh relevance
Entity match (olaparib); Patient population match (recurrent)
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govhigh relevance
Entity match (olaparib); Patient population match (recurrent)
FDA document
View source
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
ClinicalTrials.govhigh relevance
Entity match (olaparib); Patient population match (recurrent)
FDA document
View source
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
ClinicalTrials.govhigh relevance
Entity match (oncology); Patient population match (recurrent)
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca); Patient population match (recurrent)
FDA document
View source
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
ClinicalTrials.govhigh relevance
Entity match (olaparib)
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govhigh relevance
Entity match (oncology)
FDA document
View source
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated
Humanexa Signalshigh relevance
Entity match (oncology)
Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Humanexa Signalshigh relevance
Entity match (oncology)
Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched
Humanexa Signalshigh relevance
Entity match (oncology)
Phase III Trial of Herceptin Hylecta or Phesgo with Chemotherapy for HER2 Positive Endometrial Cancer
Humanexa Signalshigh relevance
Entity match (endometrial cancer)

RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Entity match (endometrial cancer)
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedhigh relevance
Entity match (endometrial cancer)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Entity match (oncology)
FDA document
View source
Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
ULK1's role in cancer progression and its emerging therapeutic potential.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AstraZeneca
Olaparib
Endometrial Cancer
Oncology

Commercial impact

high

Successful trial results could lead to increased market share for the involved therapies, potentially establishing them as new standards of care, which would drive revenue growth.

Regulatory impact

medium

The trial outcomes may influence future regulatory approvals and treatment guidelines, impacting how these therapies are positioned in the market.

What to watch

Key milestones include interim results and overall survival data from the trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.